Evaluating the Role of Cetuximab in Metastatic Colorectal Cancer
Benjamin Weinberg, MD, discusses his treatment decisions for patients with metastatic colorectal cancer and the role of cetuximab in this patient population.
Related Articles
Patient Case: A 58-year-old Man With Hematuria and Abdominal Pain
Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, while considering the most recent clinical…
LITESPARK-005 Trial of Belzutifan Shows Survival Benefits in Advanced Clear Cell RCC
A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear…
Gadgeel’s Preview of Key ESMO 2024 Findings in Lung Cancer
Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.
ESMO Congress
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
LITESPARK-005 Trial of Belzutifan Shows Survival Benefits in Advanced Clear Cell RCC
A statistically significant improvement in progression-free survival and objective response rate was seen with belzutifan treatment in patients with previously treated patients with advanced clear…
In SCLC, Upfront BMS-986012 Plus Nivolumab/Chemotherapy Has Potential
The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to…
The Journey to Holistic Care for Childhood Cancer Patients
As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to…
Lenvatinib/Pembrolizumab Combo Shows Promise in Thymic Epithelial Tumors
Data from the phase 2 PECATI trial support the use of lenvatinib plus pembrolizumab as a potential standard treatment for patients with advanced B3-thymoma and…
Consolidation Durvalumab Shows Consistent Survival Improvements in LS-SCLC Subgroups
The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of…
No DFS Benefit Seen With Adjuvant Durvalumab Across NSCLC PD-L1 Subgroups
The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung cancer, regardless of PD-L1 expression.